mesoderm specific transcript pseudogene 4Genealiases: []
Q-omics provides the consensus-scored MESTP4 profile across patient tissues and cancer cell-line models. MESTP4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MESTP4 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, MESTP4 RNA expression shows 8,810 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, LUAD, and GBM as cancer lineages where MESTP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MESTP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MESTP4 survival associations across molecular data types. MESTP4 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MESTP4 RNA expression–survival associations across cancer types. High MESTP4 expression shows unfavorable associations in CESC, STAD, ACC, MESO, CHOL and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MESTP4 RNA expression.
This table summarizes MESTP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MESTP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MESTP4 shows higher tumor expression in LUAD. The LUAD box plot shows higher MESTP4 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .021).
This table shows molecular features associated with MESTP4 in patient tissues and cancer cell lines. In patient samples, MESTP4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
